|
Edward W. Bernton, M.D., Medical Director, joined Protalex in 2007, after having spent four years as Scientific Director at the PAREXEL Clinical Pharmacology Research Unit in Baltimore, MD. While there, he supervised protocol design, project management, business development, biometrics, medical writing, and product-development consulting services. In the past, Dr. Bernton has also served in regulatory affairs and medical groups at both PAREXEL and Quintiles, and as Chief Science Officer and Medical Director of Analytica Therapeutics. Prior to that, Dr. Bernton was Medical Director of Cytimmune Sciences, where he initiated Phase I studies for a novel oncology product. Dr. Bernton has 12 years industry experience in pre-clinical product development planning and regulatory strategy for small molecules and biologics, early-phase clinical program design, and clinical pharmacology. He has published over 30 research papers and was an active researcher in endocrinology, pharmacology, and immunology during his tenure at the Walter Reed Army Institute of Research. Dr. Bernton received his M.D. from Georgetown University in 1978 and is board-certified in Internal Medicine and Allergy/Immunology/Asthma, and board-eligible in Diagnostic Laboratory Immunology. Dr. Bernton is particularly skilled in supporting product development at the pre-clinical to clinical interface, which requires joint expertise in pharmacology, clinical immunology, and experimental medicine. | 